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OBJECTIVES: The primary objectives of this study were to estimate the average costs 
during the initial phase of care (year of diagnosis) among West Virginia (WV)-Medicare 
beneficiaries with breast cancer (BC) and compare it with the national estimates from 
the Surveillance, Epidemiology, End Results (SEER)-Medicare database using a linear 
decomposition technique. METHODS: A retrospective observational study was con-
ducted where the study cohorts consisted of elderly women age > 66 with incident 
BC between 2003 and 2006 in WV-Medicare and SEER-Medicare. Total costs were the 
actual medical payments for all services derived from Medicare files. Generalized 
linear regressions with log link and gamma distribution were performed. Blinder-
Oaxaca decomposition was conducted to examine the extent to which predisposing, 
enabling, need-related, healthcare use and external healthcare environmental factors 
contributed to the differences in the average costs. RESULTS: Total average costs for 
WV-Medicare cohort during the initial phase of care were lower ($19,875) as compared 
to the SEER-Medicare cohort ($22,881), a difference of $3,006. After adjusting for other 
factors, the difference was $549 and remained significant. Only 16% of the difference 
in the average costs between the two cohorts were explained by the independent 
variables included in the model. Enabling resources (6.85%), healthcare use (7.53%) 
explained most of the differences in costs. CONCLUSIONS: Total average costs of BC 
care were lower in a rural state compared to the national estimates. The differences 
in the costs were not explained by the patient-level factors included in the model.
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OBJECTIVES: Patient care burden to health professionals (HPs) and health care 
institutions for many disorders, including agitation in schizophrenia or bipolar I 
disorder, may not be fully captured through claims data and/or medical records. 
The study objective was to assess this burden, specifically for agitated patients with 
schizophrenia and bipolar I disorder who visit emergency departments or psychiatric 
emergency service units. METHODS: This study consists of one-on-one qualitative 
telephone interviews followed by a web-based survey. Interviews are conducted with 
10 emergency setting-based HPs (physicians, nurses, aides, ED/hospital administra-
tors, and social workers). Interviews follow a semi-structured guide with specific 
probes/prompts to capture the intangible impacts that drive indirect and direct costs 
of care. The guide includes general open-ended questions and specific questions on 
specific areas of impact, including physical, psychological, and emotional impacts 
on the HP, as well as impacts on job performance and satisfaction. The interview 
findings inform a web-based survey (administered to a similar mix of 200 treating 
HPs) which includes multiple choice questions, rating questions, ranking exercises, 
and open-ended questions. The survey collects data such as characteristics of HPs, 
burden of treating patients including use of restraints, isolation, boarding, length of 
stay, staff abuse and injury, and direct costs. RESULTS: The results from the on-going 
interviews and web survey of the indirect burden of treating these patients with 
agitation will be reported. CONCLUSIONS: This interview and survey methodology 
comprehensively assesses the full burden of treating agitation in schizophrenia or 
bipolar I disorder patients from the point of view of various HPs. This study will help 
bridge the gap on the indirect burden of treating patients with agitation, and can be 
used to complement direct burden of care data. This methodology can be applied 
to other disease areas to comprehensively assess the burden of patient treatment.
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OBJECTIVES: The objective of this retrospective database analysis was to examine 
the most common reasons for hospitalization and the associated burden of these 
hospitalizations among children in the United States. METHODS: Data from the 2012 
Healthcare Cost and Utilization Project’s (HCUP) Kids’ Inpatient Database (KID) were 
assessed for this analysis. The top-10 most common primary discharge diagnoses 
(ICD-9-CM) were obtained for children aged 1-4, 5-9, and 10-14 years. The length of 
stay (LOS) and costs for each of these admissions were reported. Costs were esti-
mated based on charges and hospital specific cost-to-charge ratios. RESULTS: The 
most common primary discharge diagnoses were: children 1-4 years (N= 481,859), 
pneumonia (N= 41,716) and acute asthma exacerbation (N= 27,453); children 5-9 years 
(N= 321,535), pneumonia (N= 20,240) and acute asthma exacerbation (N= 18,147); and 
children 10-14 (N= 359,000), years acute appendicitis (N= 18,487) and affective psy-
choses (N= 13,221). Across all age groups, pneumonia, asthma, and chemotherapy 
administration were included in the top-10 most common diagnoses. For children 1-4 
years, chemotherapy administration had the greatest burden (mean LOS= 5.0 days, 
mean costs= $12,438; LOS range: 1.4 croup-2.6 pneumonia; cost range: $2,629 croup-
$5,164 acute bronchiolitis). For children 5-9 years, affective psychoses had the longest 
LOS (mean LOS= 8.1 days; range: 1.2 fractured humerus-4.8 acute appendicitis) and 
acute appendicitis had the greatest cost (mean cost= $12,104; range: $3,204 dehy-
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OBJECTIVES: This analysis evaluated the impact of non-medical switching (switch-
ing for a reason that is not medically related such as due to costs) from adali-
mumab (ADA) to another injectable biologic (certolizumab, golimumab, etanercept, 
or ustekinumab) on healthcare costs in patients with rheumatoid arthritis, psoriasis, 
psoriatic arthritis, ankylosing spondylitis, or Crohn’s disease following a formu-
lary management change by large national payor. METHODS: Medically stable 
adult patients with ≥ 90 days continuous ADA use were identified in OptumInsight 
database (07/01/2012-06/30/2013). Patients who subsequently switched to another 
biologic (index date) following a payer formulary change and for no apparent medi-
cal reason between 01/01/2013-06/30/2013 were defined as non-medical switchers. 
Patients who remained on ADA therapy during this period were defined as main-
tainers and their index dates were chosen randomly. Patients with hospitaliza-
tions, emergency department (ED) visits, or substantial increases in ADA dose 6 
months pre-index (baseline) were excluded to ensure medical stability. Outcomes 
included all-cause and indication-related medical (hospitalizations, ED visits, and 
outpatient visits) and total (medical and pharmacy) costs. T-tests and multivariate 
regression analyses were used to compare cohorts in costs incurred during the 6 
months post-index (follow-up) and in costs difference from baseline to follow-
up. RESULTS: Mean age was 46 and 48 years, respectively, for maintainers (n= 2,693) 
and switchers (n= 985). Switchers incurred significantly higher all-cause medical 
costs ($4,557 vs $3,310; P= .0011) and total costs ($21,996 vs $17,379, P< .0001) during 
follow-up vs maintainers. Differences from baseline to follow-up were significantly 
greater for non-medical switchers compared to maintainers in all-cause medical 
costs ($1,476, P< .0001) and total costs ($6,355, P< .0001). Adjusted regression analyses 
and indication-specific results yielded consistent findings. CONCLUSIONS: These 
real-world analyses of patients stabilized on ADA demonstrated that maintaining 
therapy with ADA was associated with significantly less healthcare expenditures 
compared to switching to another anti-TNF for a non-medical reason.
PHS27
increaSeD HealtHcare utilization aSSociateD witH obeSity
Hoshen M.B., Balicer R.
Clalit Health Services, Tel Aviv, Israel
OBJECTIVES: The obesity pandemic is driving an increase in healthcare utilization. 
However the specific breakdown of increased morbidity and associated usage requires 
linked primary care, chronic disease and hospitalization registries. Clalit Health 
Services (CHS), with its comprehensive stable database of over 4 million members, 
provides a strong base for comparing morbidity and health care utilization between 
obese and non-obese patients, thus laying the groundwork for informed health 
care policy. METHODS: We selected two random samples, 10,000 obese (BMI> 30 1/
Jan/2011) patients and 10,000 not-overweight (BMI< = 25) from the CHS database aged 
25-74, matching CHS population age standard. We linked both datasets to the chronic 
disease registry, identifying the following diagnoses: diabetes, ischemic heart disease 
(IHD), congestive heart failure (CHF), hypertension (HTN), s/p cerebral vascular acci-
dent (CVA), chronic renal failure (CRF), and rheumatoid arthritis (RA). We compared 
disease prevalence, hospital admission rates and total cost for the groups. RESULTS: 
The prevalence of all chronic disease The greatest effect was seen for diabetes 
(RR= 3.39 CI 3.15-3.65), CHF (2.23 1.79-2.78), and HTN (2.34 2.22-2.46) but also for IHD, 
CVA , CRF and RA (1.77, 1.69, 2 and 1.37 respectively). Risk of hospitalization over 
three years was increased (1.34 1.28-1.42) and, on average, there were 58% increase in 
hospitalizations and 303% overall increased cost of healthcare compared to non-obese 
patients. CONCLUSIONS: The presence of obesity increases risk of severe comorbidi-
ties within the general population. Obesity increases risk of any hospitalization and 
both total cost and total hospital admissions among patients. Our findings suggest 
the need for intensive proactive health care policy to prevent and remedy obesity to 
prevent the financial collapse of over-stretched health organizations, and indicate the 
potential for cost-effectiveness of interventions, whether behavioral, pharmaceutical, 
or surgical, or combinations thereof.
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OBJECTIVES: This study analyzes the costs of hospital care to children with TBI before 
and after a pediatric neurocritical care center (PNCC) implementation. A previous 
study1 with this sample showed improved clinical outcomes. METHODS: This retro-
spective cohort study includes 63 patients in the pre-PNCC group, and 59 post-PNCC 
patients. We merged demographic and clinical data with cost data from the hospital 
finance office for the same patient hospitalization. Outcome variables included total 
cost percentage ((direct + overhead)/median total cost pre-PNCC*100%), and overall 
length of stay (LOS) and PICU LOS. Mann-Whitney U’s, chi-squares, and multiple linear 
regression were utilized. RESULTS: Gender, race, injury mechanism, age at admis-
sion, Glasgow Coma Score, and PRISM III score were similar in the pre and post-PNCC 
groups (p> 0.05 for all). While PICU length of stay (LOS) increased post-PNCC (median 
(IQR) pre: 11 (5-15) v. post: 14 (7-22), p = 0.02), the overall hospital LOS did not change 
(pre: 32 (14-55) v. post 37 (17-58), p = 0.42. Total cost percentage increased from a 
median(IQR) of 100% (61-181%) to 143% (95-218%), p = 0.04. After adjusting for covari-
ates, total costs percentage was still significant post-PNCC compared to pre-PNCC 
(b(se) = 16.2(5.4), p = 0.003). LOS and PICU LOS were also positively related to total costs 
(b(se) = 2.6(0.1) and 2.6 (0.4) respectively, p < 0.0001 for both). CONCLUSIONS: After 
adjusting for PICU LOS, PNCC implementation remained associated with an increase 
in total cost. One would need to look outside of the initial hospitalization to determine 
if PNCC is cost effective given the improved clinical outcomes. 1 Pineda et al. Effect 
